Amplyx Pharmaceuticals, Inc.
http://amplyx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amplyx Pharmaceuticals, Inc.
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
Big Pharma Must Diversify To Tackle Antimicrobial Resistance
Big pharma must bet on biotech if the industry is to tackle the looming issue of superbugs, argues the Access To Medicine Foundation.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Arix Bioscience plc
- Pfizer Inc.